Volume 23, Issue 4 (7-2024)
JRUMS 2024, 23(4): 367-373 |
Back to browse issues page
Ethics code: 1
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hassanshahi J. Challenges and Strategies of Chronic Kidney Disease Care in People with Type 2 Diabetes: A Point of View. JRUMS 2024; 23 (4) :367-373
URL: http://journal.rums.ac.ir/article-1-7429-en.html
URL: http://journal.rums.ac.ir/article-1-7429-en.html
Rafsanjan University of Medical Sciences
Full-Text [PDF 244 kb]
(292 Downloads)
| Abstract (HTML) (902 Views)
Full-Text: (545 Views)
Challenges and Strategies of Chronic Kidney Disease Care in People with Type 2 Diabetes: A Point of View
Jalal Hasanshahi[1]
Received: 09/06/24 Sent for Revision: 22/06/24 Received Revised Manuscript: 03/07/24 Accepted: 06/07/24
The prevalence of chronic kidney disease (CKD) in people with type 2 diabetes mellitus (T2DM) is a critical challenge that healthcare providers face. Lifestyle modification, dietary changes, and regular exercise are essential in preventing CKD in people with T2DM. Along with lifestyle interventions, screening, early diagnosis, and then drug treatments have emerged as powerful tools against diabetic kidney disease. A therapeutic approach focused on blood pressure and glucose control is essential to treat CKD. To improve outcomes and reduce the detrimental impact of CKD in patients with T2DM, healthcare providers must be aware of new strategies for kidney protection. By implementing a comprehensive approach that uses lifestyle changes, timely screening, proven pharmacological interventions, and new therapeutic agents, we can work to improve outcomes.
Key words: Chronic kidney disease, Type 2 diabetes, Prevention, Screening, Drug interventions.
Funding: None.
Conflict of interest: None declared.
Ethical considerations: Not applicable.
Authors’ contributions:
- Conceptualization: Jalal Hasanshahi
- Methodology: Jalal Hasanshahi
- Data collection: Jalal Hasanshahi
- Formal analysis: Jalal Hasanshahi.
- Supervision: Jalal Hasanshahi
- Project administration: Jalal Hasanshahi
- Writing - original draft: Jalal Hasanshahi
- Writing - review and editing: Jalal Hasanshahi
(Corresponding Author) Tel: (034) 31315083, Fax: (034)31315003, E-mail: hasanshahij@gmail.com
Jalal Hasanshahi[1]
Received: 09/06/24 Sent for Revision: 22/06/24 Received Revised Manuscript: 03/07/24 Accepted: 06/07/24
The prevalence of chronic kidney disease (CKD) in people with type 2 diabetes mellitus (T2DM) is a critical challenge that healthcare providers face. Lifestyle modification, dietary changes, and regular exercise are essential in preventing CKD in people with T2DM. Along with lifestyle interventions, screening, early diagnosis, and then drug treatments have emerged as powerful tools against diabetic kidney disease. A therapeutic approach focused on blood pressure and glucose control is essential to treat CKD. To improve outcomes and reduce the detrimental impact of CKD in patients with T2DM, healthcare providers must be aware of new strategies for kidney protection. By implementing a comprehensive approach that uses lifestyle changes, timely screening, proven pharmacological interventions, and new therapeutic agents, we can work to improve outcomes.
Key words: Chronic kidney disease, Type 2 diabetes, Prevention, Screening, Drug interventions.
Funding: None.
Conflict of interest: None declared.
Ethical considerations: Not applicable.
Authors’ contributions:
- Conceptualization: Jalal Hasanshahi
- Methodology: Jalal Hasanshahi
- Data collection: Jalal Hasanshahi
- Formal analysis: Jalal Hasanshahi.
- Supervision: Jalal Hasanshahi
- Project administration: Jalal Hasanshahi
- Writing - original draft: Jalal Hasanshahi
- Writing - review and editing: Jalal Hasanshahi
[1]- Associate Prof. of Physiology, Dept. of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran, ORCID: 0000-0003-3754-8152
(Corresponding Author) Tel: (034) 31315083, Fax: (034)31315003, E-mail: hasanshahij@gmail.com
Type of Study: Research |
Subject:
غدد
Received: 2024/06/23 | Accepted: 2024/07/21 | Published: 2024/07/20
Received: 2024/06/23 | Accepted: 2024/07/21 | Published: 2024/07/20
References
1. Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GC, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes, obesity and metabolism 2020; 22(9): 1607-18.
2. Komenda P, Rigatto C, Tangri N. Screening strategies for unrecognized CKD. Clinical Journal of the American Society of Nephrology 2016; 11(6): 925-7.
3. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. Jama 2015; 313(8): 837-46.
4. Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. American Journal of Nephrology 2021; 52(2): 98-107.
5. Fenta ET, Eshetu HB, Kebede N, Bogale EK, Zewdie A, Kassie TD, et al. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetology & Metabolic Syndrome 2023; 15(1): 245.
6. Garla V, Yanes-Cardozo L, Lien LF. Current therapeutic approaches in the management of hyperglycemia in chronic renal disease. Reviews in Endocrine and Metabolic Disorders 2017;18:5-19.
7. Copur S, Onal EM, Afsar B, Ortiz A, van Raalte DH, Cherney DZ, et al. Diabetes mellitus in chronic kidney disease: biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. Journal of Diabetes and its Complications 2020; 34(11): 107707.
8. Hong YS, Kim H, Zhao D, Cho A. Chronic kidney disease on health-related quality of life in patients with diabetes mellitus: a national representative study. Journal of Clinical Medicine 2021; 10(20): 4639.
9. Tonelli M, Tiv S, Anand S, Mohan D, Garcia GG, Padilla JAG, et al. Diagnostic yield of population-based screening for chronic kidney disease in low-income, middle-income, and high-income countries. JAMA network open 2021; 4(10): 212-26.
10. Dunkler D, Kohl M, Heinze G, Teo KK, Rosengren A, Pogue J, et al. Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. Kidney international 2015; 87(4): 784-91.
11. Mirabelli M, Chiefari E, Arcidiacono B, Corigliano DM, Brunetti FS, Maggisano V, et al. Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases. Nutrients 2020; 12(4): 1066.
12. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes care 2022; 45(12): 3075-90.
13. Kleinaki Z, Kapnisi S, Theodorelou-Charitou S-A, Nikas IP, Paschou SA. Type 2 diabetes mellitus management in patients with chronic kidney disease: an update. Hormones 2020; 19: 467-76.
14. von Scholten BJ, Kreiner FF, Rasmussen S, Rossing P, Idorn T. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: From randomised trials to clinical practice. Therapeutic Advances in Endocrinology and Metabolism 2022; 13: 204-20.
15. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New England journal of medicine 2020; 383(23): 2219-29.
16. Singh-Franco D, Harrington C, Tellez-Corrales E. An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease. SAGE Open Medicine 2016; 4: 2050312116659090.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
